Recent blog posts
NCT07656909 Sirolimus Kaposiform Hemangioendothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07656909 Sirolimus Kaposiform Hemangioendothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07656909, evaluating Sirolimus in Kaposiform Hemangioendothelioma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07657273 Yttrium[90Y] carbosphere Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07657273 Yttrium[90Y] carbosphere Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07657273, evaluating Yttrium[90Y] carbosphere in Hepatocellular Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
Pancreatin/Ursodeoxycholic Acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Pancreatin/Ursodeoxycholic Acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pancreatin/Ursodeoxycholic Acid: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
JPRN-jRCT2051260087 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2051260087 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2051260087, evaluating Rinatabart Sesutecan in Gastrointestinal Neoplasms: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
Vitamin B2/Aspirin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Vitamin B2/Aspirin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Vitamin B2/Aspirin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
NCT07655661 Tislelizumab stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07655661 Tislelizumab stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07655661, evaluating Tislelizumab in stomach adenocarcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
Ilaprazole/Sodium Bicarbonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Ilaprazole/Sodium Bicarbonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ilaprazole/Sodium Bicarbonate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Sufentanil Citrate/Ketamine Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Sufentanil Citrate/Ketamine Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sufentanil Citrate/Ketamine Hydrochloride: Phase 2/3. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
NCT07655817 Magnesium Carbonate Emergence Delirium Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07655817 Magnesium Carbonate Emergence Delirium Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07655817, evaluating Magnesium Carbonate in Emergence Delirium: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
Pregabalin naproxencarbil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Pregabalin naproxencarbil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pregabalin naproxencarbil: Phase 2/3. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
NCT07655804 Calcitonin Salmon Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07655804 Calcitonin Salmon Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07655804, evaluating Calcitonin Salmon in Herpes Zoster: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07656688 HUC1-394 Dry Eye Syndromes Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07656688 HUC1-394 Dry Eye Syndromes Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07656688, evaluating HUC1-394 in Dry Eye Syndromes: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →